FREE DESIGN AUDIT
Free Design Audit Available - Click Here for Details

Blog

- March 4, 2026

XYRA Announces Issuance of US Patent to Reduce the Risk of Heart Failure or Strokes by Reducing the Number and Duration of Atrial Fibrillations

March 4, 2026

LOS ALTOS, Calif., March 4, 2026 /PRNewswire/ — XYRA LLC announces that the US Patent and Trademark Office (USPTO) has issued a patent (No. 12,551,706) protecting the use of dose adjusted budiodarone for the treatment of atrial fibrillation (AF), with monitoring to correspondingly reduce or delay the risk of stroke and/or congestive heart failure.

Read More »

Airiver Medical Granted FDA’s Breakthrough Device Designation for Pulmonary Drug Coated Balloon to Treat Central Airway Stenosis

March 4, 2026

BROOKLYN PARK, Minn., March 4, 2026 /PRNewswire/ — Airiver Medical, a clinical stage company developing technologies to help patients who suffer from certain respiratory tract conditions, was granted designation as a Breakthrough Device from the U.S. Food and Drug Administration (FDA) for its Airiver Pulmonary Drug Coated Balloon (DCB) to treat central airway stenosis.

Read More »

Monteris Medical Announces New Study Showing NeuroBlate® Laser Ablation May Enhance Immunotherapy Response, Providing Significant Overall Survival Improvement in Recurrent High Grade Brain Tumors

March 4, 2026

MINNETONKA, Minn., March 4, 2026 /PRNewswire/ — Monteris Medical, the leader in minimally invasive neurosurgical technology with its NeuroBlate® System, announced today that a newly published randomized prospective study in the distinguished journal Nature Communications suggests that laser interstitial thermal therapy (LITT) using NeuroBlate may enhance the effectiveness of the immunotherapy drug pembrolizumab (Keytruda®) for patients with recurrent high grade astrocytoma, including glioblastoma (GBM).

Read More »